Now open: VHIO’s first institutional call for applications for pre-doctoral research fellowships
Barcelona, September 30, 2021. The Vall d'Hebron [...]
Ivosidenib as a promising new contender against advanced cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous [...]
ecancer catches up with VHIO’s Enriqueta Felip & Cristina Saura on new therapeutic avenues against NSCLC and breast cancer, respectively
Reflective of the relevance of just some [...]
VHIO at ESMO 2021: the promise of potential new therapeutic avenues against NSCLC
Featuring among our pre-selection pick of VHIO [...]
VHIO at ESMO 2021: reporting on the impact of COVID-19 on cancer patients and clinical research
The OnCOVID registry includes over 2700 European [...]
VHIO at ESMO 2021: reporting treatment advances against neuroendocrine and endocrine tumors
Barcelona, September 21, 2021. Featuring among our pre-selection [...]
Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage NSCLC
Barcelona, September 20, 2021. With an estimated 2.2 [...]
VHIO ‘on the ground’ at ESMO 2021: reporting advances in breast cancer treatment
During this week’s virtual 2021 Annual Congress [...]
VHIO at ESMO 2021: biomarker analysis & molecular tumor profiling to more effectively combat colorectal cancer
Barcelona, September 18, 2021. Featuring among our pre-selection [...]
Vall d’Hebron case study demonstrates the importance of COVID-19 vaccination in patients with malignant pleural mesothelioma
Results from a descriptive case study presented [...]